Role of Sympathetic Nervous System in Experimental Hypertension and Diabetes Mellitus

References

• Grewal R. S., Kaul C. L. Mechanism of the antagonism of the hypotensive effect of guanethidine by propranolol. Br J Pharmac 1970; 38: 771–775
   PubMed Web of Science ®Google Scholar
• Mark A. L. The sympathetic nervous system in hypertension: a potential long term regulator of arterial pressure. J Hypertension 1996; 5: 159–165
   Google Scholar
• Dorr L. D., Brody M. J. Preliminary observations on the role of sympathetic nervous system in development and maintenance of experimental renal hypertension. Proc Soc Exp Biol Med 1966; 123: 155–158
   PubMed Web of Science ®Google Scholar
• Willard P. W., Fuller R. W. Functional significance of the sympathetic nervous system in the production of hypertension. Nature (Lond) 1969; 233: 417–418
   Google Scholar
• Ayitey-Smith E., Varma D. R. An assessment of the role of the sympathetic nervous system in experimental hypertension using normal and immunosympathectomised rats. Br J Pharmac 1970; 40: 175–185
   PubMed Web of Science ®Google Scholar
• Grewal R. S., Kaul C. L. Importance of sympathetic nervous system to the development of renal hypertension in the rat. Br J Pharmac 1971; 42: 497–504
   PubMed Web of Science ®Google Scholar
• Finch L., Leach G. D.H. The contribution of the sympathetic nervous system to the development and maintenance of experimental hypertension in the rat. Br J Pharmac 1970; 39: 317–324
   PubMed Web of Science ®Google Scholar
• MeCubbin J. W., Page I. H. Renal pressor system and neurogenic control of arterial pressure. Circulation Res 1963; 12: 553–559
   Web of Science ®Google Scholar
• Koletsky S., Pritchard W. H. Vasopressor material in experimental renal hypertension. Circulation Res 1963; 13: 552–556
   PubMed Web of Science ®Google Scholar
• Pritchard W. H., Ormond Jun A. P., Koletsky S. Differences in levels of circulating vasopressor material in dogs with acute and chronic renal hypertension. Proc Soc Exp Biol Med 1964; 117: 127–131
   PubMed Web of Science ®Google Scholar
• Hano T., Nishio J. Hypertension in the patients with impaired glucose tolerance. Nippon Rinsho 1996; 54: 2687–2691
   PubMedGoogle Scholar
• Corry D. B., Tuck M. L. Glucose and insulin metabolism in hypertension. Am J Nephrol 1966; 16: 223–236
   Google Scholar
• Thoenen H., Tranzer J. P. Chemical sympathectomy by selective destruction of adrenergic nerve endings with 6-hydroxydopamine. Naunyn-Schmiedeberg's Arch Exp Path Pharmak 1968; 261: 271–288
   PubMedGoogle Scholar
• Goldblatt H., Lynch J., Hanzal R. F., Summerville W. W. Studies on experimental hypertension. J Exp Med 1934; 59: 347–379
   PubMedGoogle Scholar
• Byrom F., Wilson C. Plethysmographic method for measuring systolic blood pressure in the intact rat. J Physiol (Lond) 1938; 93: 301–304
   Google Scholar
• Crout J. R., Creveling C.R, Udenfriend S. Norepinephrine metabolism in the rat brain and heart. J Pharmac Exp Ther 1961; 132: 269–277
   PubMed Web of Science ®Google Scholar
• Bertier A., Carlsson A., Rosengren E. A method for the fluorimetric determination of the adrenaline and noradrenaline in tissues. Acta Physiol Scand 1958; 44: 273–292
   PubMedGoogle Scholar
• Pisano J. J., Crout J. R., Abraham D. Determination of 3-methoxy-4-hydroxymandelic acid in urine. Clinica Chim Acta 1962; 7: 285–291
   PubMed Web of Science ®Google Scholar
• Folin O. K.O. Cited in Oscar, Hawk's physiological chemistry; 14th ed. (McGraw-Hill, New York). J Biol Chem 1914; 17: 469
   Google Scholar
• Bourne G. H. in The Rhesus Monkey, G.J. Bourne. Academic Press, New York 1975; 63
   Google Scholar
• Itaya K., Ui M. Colorimetric determination of free fatty acids in biological fluids. J Lipid Res 1965; 6: 16–20
   PubMed Web of Science ®Google Scholar
• Finch L., Leach G. D.H. Does the adrenal medulla contribute to the maintenance of experimental hypertension. Eur J Pharmac 1970; 11: 388–391
   PubMed Web of Science ®Google Scholar
• Mueller R. A., Thoenen H., Axelrod J. P. Adrenal tyrosine hydroxylase. Compensatory increase in activity after chemical sympathectomy. Science 1969; 163: 468–469
   Google Scholar
• Hamberger B., Levi Montalcini R., Norberg K. A., Sgoquist F. Monoamines in immunosympathectomizedrats. Int J Neuropharmac 1965; 4: 91–95
   PubMedGoogle Scholar
• Cegrell L. The occurance of biogenic monoamines in mammalian endocrine pancreas. Acta Physiol Scand Suppl 1968; 314: 60
   Google Scholar
• Christensen N. J. Plasma catecholamines in long term diabetics with and without neuropathy and in hypophysectomised subjects. J Clin Invest 1972; 51: 779–787
   PubMed Web of Science ®Google Scholar
• Christensen N. J. Plasma norepinephrine and epinephrine in untreated diabetic during fasting and after insulin administration. Diabetes 1974; 23: 1–8
   PubMed Web of Science ®Google Scholar
• Christlieb A. R. Diabetic and hypertension vascular disease mechanism and treatment. Am J Cardiol 1973; 32: 592–606
   PubMed Web of Science ®Google Scholar
• Montanari R., Custan E., Beaven B.B., Brodie M. A. Turnover rates of norepinephrine in heart of infract mice rats and guinea pigs using tritiated norepinephrine. Life Sci 1963; 29: 232–240
   Google Scholar
• Harrower A. D.B. Cardiovascular disease in diabetic mellietus. Br J Clin Pract 1977; 31: 47–51
   PubMedGoogle Scholar
• Kawashima H., Igarashi T., Nakajima Y., Akiyama Y., Usuki K., Ohtake S. Chronic hypertension induced by streptozotocin in rats. Naunyn-Schimedebergs Arch Pharmac 1978; 305: 123–126
   Google Scholar
• Kaul C. L., Grewal R. S. Vascular reactivity in streptozotocin induced diabetic rat. Pharm Res Comm 1980; 12: 945–958
   PubMedGoogle Scholar
• Christlieb A. R. Diabetes and hypertensive vascular disease. Mechanisms and Treatment. Am J Cardiol 1973; 32: 592–606
   PubMed Web of Science ®Google Scholar
• Clements R. S., Morrison A. D., Weinegard A. I. Polyol pathway in aorta: regulation by hormones. Science 1969; 166: 1007–1008
   PubMed Web of Science ®Google Scholar